Robert Groves, MD, of Banner | Aetna discusses the challenges primary care practitioners (PCPs) face when addressing social determinants of health (SDOH).
Robert Groves, MD, of Banner | Aetna explained the challenges primary care practitioners (PCPs) face when addressing social determinants of health (SDOH). This topic was thoroughly discussed at the The American Journal of Managed Care®’s Institute for Value-Based Medicine® (IVBM) in Phoenix, Arizona, on December 12, 2023. Groves was a co-chair of the event.
Groves currently serves as the first executive vice president and chief medical officer of a new health insurance plan in Arizona formed as a joint venture between Banner Health and Aetna. As part of his role, he provides corporate strategy and physician leadership in population health management to ensure the delivery of high-quality clinical performance and evidence-based utilization.
Transcript
The IVBM was centered around the challenges PCPs face in addressing SDOH issues. Could you please explain what some of these challenges are?
There are lots of challenges. First of all, asking PCPs to do one more thing. This is a specialty that's under siege. We have not supported primary care effectively for decades, and we're losing PCPs right and right. You may argue that some of that will be replaced by transactional services in retail with some of the larger providers, like Amazon, CVS, et cetera. But there are really 2 kinds of patients; this is an artificial distinction, and yes, you can divide them up more.
There are the kinds of patients who want transactional services; those are usually not life-threatening issues. You got a sore throat, or you jammed your finger, whatever it is that brings you into an urgent care or one of those facilities. Primary care is about relationships long term, and in order to serve the second set of patients, and those are the ones with serious chronic illness, or who have had a serious health event in their lives, they're usually looking for somebody they can trust and develop a relationship with over time, somebody who can be the quarterback for their care team. Those kinds of physicians, not through their own fault, are fewer and further between.
When we ask doctors to see patients in 10 minutes, to see new patients in 30 minutes, it's asking too much. You can't really understand patients, you can't understand their motivations, and you can't even get a full picture of their disease if you have that limited amount of time with them on an infrequent basis, and I consider monthly infrequent with regards to the rest of our lives.
I think that we brought that problem to the floor a little bit, as well, not specifically, not directly, but it's part of the overall mix. We need to free up time for PCPs to getting back to what PCPs do best, which is establishing relationships with their patients, developing trust so that they can develop influence in the behaviors of those folks.
We also reviewed data that's very clear that only about 15% to 20% of health outcomes, particularly in terms of longevity health span, are accounted for by the $4.5 trillion that we spend every year. Most of it has to do with genetics, but a huge chunk of it has to do with behaviors, and then a chunk of it has to do with zip code with context. In other words, is there pollution in the community? Is it a food desert? Is there violence? All of those sorts of issues come into play.
What we spend $4.5 trillion on is really rescue medicine. It's after a chronic disease has developed, after an accident has happened, it's trying to salvage those folks whose context has led them to the point in time where they have a serious chronic illness. Now, some of that is good, we're living a lot longer and on balance; the modern health care rescue system adds 7 years of life, and, by the way, at my age, I value 7 years of life, I want that.
When we try to charge that system with the health of a population, we have missed the whole point because we are rescue medicine. If you want a healthy population, the literature has been clear for some time. What you do is you invest in education and opportunity; you have a solid safety net in place for those who fall through the cracks, you guarantee the availability of not just rescue medicine but prevention to all citizens.
If your goal is to improve healthspan and lifespan, when we compare ourselves to other countries, we find we're ranked 32. It's not because of our rescue medicine system because it's simply not designed to do that. We excel, we lead the world in rescue medicine, there's absolutely no doubt about that, hands down, no discussion. If you get hit by a car, if you develop cancer, if you have a heart attack, there is no better place to be for health care. We, still, in the world, get the best outcomes, and we lead the world in innovation.
So, the question we have to ask ourselves is, what is the job to be done? Do we want to continue to devote all of our resources to rescue medicine? Or, is it time to support social services, social policies, and public health so that we can actually have an increase in healthspan and lifespan? That's, as a society, a question we have to answer.
Joanne Mizell: Lifestyle Modification Programs Take Holistic Aim at Metabolic Disease
May 1st 2024Joanne Mizell shares insurer strategies in addressing the escalating rates of metabolic diseases, highlighting the importance of holistic treatment methods like lifestyle modification programs, which integrate nutrition, physical activity, and community engagement.
Read More
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Diving Deep Into Specialty Pharmacy: Insights and Forecasts From IQVIA’s Doug Long
May 1st 2024Doug Long, MBA, vice president of industry relations at IQVIA, covered a bevy of stakeholder investment–related topics in his presentation at AXS24 on trends in specialty pharmacy, chief among them challenges facing the industry, obesity medications, generics and biosimilars, new product launches, and the outlook for the US market.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
OptumRx’s Jon Mahrt Discusses “Irresponsible” Drug Pricing for Products With Multiple Indications
April 30th 2024When the same product comes to market with additional indications, irrational pricing decisions result in ever increasing prices instead of volume translating to lower costs, said Jon Mahrt, MBA, of OptumRX.
Read More
Joanne Mizell: Lifestyle Modification Programs Take Holistic Aim at Metabolic Disease
May 1st 2024Joanne Mizell shares insurer strategies in addressing the escalating rates of metabolic diseases, highlighting the importance of holistic treatment methods like lifestyle modification programs, which integrate nutrition, physical activity, and community engagement.
Read More
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Diving Deep Into Specialty Pharmacy: Insights and Forecasts From IQVIA’s Doug Long
May 1st 2024Doug Long, MBA, vice president of industry relations at IQVIA, covered a bevy of stakeholder investment–related topics in his presentation at AXS24 on trends in specialty pharmacy, chief among them challenges facing the industry, obesity medications, generics and biosimilars, new product launches, and the outlook for the US market.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
OptumRx’s Jon Mahrt Discusses “Irresponsible” Drug Pricing for Products With Multiple Indications
April 30th 2024When the same product comes to market with additional indications, irrational pricing decisions result in ever increasing prices instead of volume translating to lower costs, said Jon Mahrt, MBA, of OptumRX.
Read More
2 Commerce Drive
Cranbury, NJ 08512